T. Rashal

发表

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.

R. Carlson, A. Shields, Lee-Anne Stayner, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer

D. Coppola, D. Sullivan, M. Malafa, 2015, Molecular Cancer Therapeutics.

Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer

D. Coppola, D. Sullivan, M. Malafa, 2015, Molecular Cancer Therapeutics.

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.

C. Hofmeister, S. Trudel, D. Reece, 2018, Blood.

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

R. Carlson, S. D'Angelo, J. Erinjeri, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)

A. Azmi, C. Hofmeister, D. Siegel, 2014 .

Abstract 4490: Selinexor (KPT-330) radio-sensitizes non-small cell lung cancer cellsin vitroandin vivo

R. Carlson, Y. Lawrence, R. George, 2015 .

888PPRECLINICAL AND EARLY CLINICAL ACTIVITY OF THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) EXPORTIN 1 (XPO1) ANTAGONIST SELINEXOR (KPT-330) IN PATIENTS (PTS) WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER (OVCA).

P. Dottino, J. Martignetti, A. Razak, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.

R. Garzon, R. Carlson, M. Andreeff, 2017, Blood.

Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa).

P. Dottino, J. Martignetti, A. Razak, 2014 .

Selinexor-Induced Thrombocytopenia Results from the Inhibition of Megakaryocyte Progenitor Cells in the Early Stage of Megakaryopoiesis

R. Carlson, J. Italiano, K. Machlus, 2014 .

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer

Richard L. Halpert, R. Sebra, Rileen Sinha, 2016, Clinical Cancer Research.

The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL)

J. Byrd, I. Flinn, R. Garzon, 2014 .

758OSELINEXOR (KPT-330), AN ORAL, SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SHOWS ANTI-PROSTATE CANCER (PRCA) ACTIVITY PRECLINICALLY & DISEASE CONTROL IN PATIENTS (PTS) WITH CHEMOTHERAPY REFRACTORY, CASTRATE-RESISTANT PROSTATE CANCER (CRPC).

A. Shields, M. Mirza, B. Klebanov, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

994PDCLINICAL ACTIVITY OF THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SELINEXOR (KPT-330) IN PATIENTS WITH HEAD & NECK SQUAMOS CELL CARCINOMA (HN-SCC).

A. Razak, M. Mirza, N. Gabrail, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase 1b food effect study of the first-in-class, oral, selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients (pts) with advanced sarcomas.

G. Schwartz, M. Gounder, A. Razak, 2014 .

Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort.

G. Pond, A. Oza, A. Shields, 2014 .

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM)

J. Byrd, G. Pond, A. Oza, 2013 .

Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

J. Byrd, G. Pond, A. Oza, 2013 .

Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)

J. Byrd, G. Pond, A. Oza, 2013 .

Selinexor, a selective inhibitor of nuclear export, inhibits human neutrophil extracellular trap formation in vitro

R. Elhasid, R. Shukrun, T. Rashal, 2022, Frontiers in Pharmacology.

Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.

I. Vergote, N. Concin, M. Mirza, 2019, Gynecologic oncology.

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.

Michael L. Wang, I. Flinn, R. Garzon, 2017, Blood.

Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Pediatric Patients with Relapsed or Refractory AML

R. Ribeiro, J. Rubnitz, H. Youssoufian, 2015 .

Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers

P. Neven, I. Vergote, T. Juhler-Nøttrup, 2016 .

A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML).

I. Flinn, R. Garzon, D. DeAngelo, 2014 .

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.

C. Hofmeister, S. Trudel, D. Reece, 2018, Blood.